Boston Scientific Corp (BSX) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Boston Scientific Corp (BSX)

42.99

-0.21 (0.47%)

as of Jul 22, 2026, 7:52:03 pm Market Open.

101 watching

Investor Insights

Jul 22, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Boston Scientific Corp (BSX-N) is experiencing a challenging period, characterized by broken momentum and technical weaknesses, as evidenced by its falling share price below the critical $50 support level and the 200-day moving average. Experts note that the company has lost its organic growth momentum, partly due to high valuations and heightened competition in the medical device space, which has affected investor sentiment. Despite being a leader in its industry with long-term potential driven by aging demographics and an increase in less invasive medical procedures, near-term performance remains uncertain. While some analysts highlight solid margins and a robust global market expansion, they caution against buying in at current levels due to the heightened risk associated with its valuation and organic growth forecasts. Overall, a wait-and-see approach appears to be the prevailing sentiment among experts.

Consensus

Cautious

Valuation

Overvalued

Similar

MDT

BUY

BDX vs. TMO

Avoid TMO because their revenues are flattening. Both trade at a high PE. BDX hasn't done much in share movement. He'd rather pay more for Boston Scientific which performs better.

Wealthica Track your Stocks in your Watch List

PAST TOP PICK

(A Top Pick Dec 28/22, Up 27%)

Still owns shares. Venture capital fund in health care business. One of most successful funds in biotech. Expecting consistent gains going forward.

HOLD

Above FMV of $40 by 22%. Growth is fairly nice. He thinks it will hold fairly well. A bouncy kind of stock.

DON'T BUY

It is at a new high in terms of price but not new highs in terms of Price/Book. There is no yield and a 25% downside risk.

BUY

It is a leader in the field so the price is at a premium for a good reason. Has had a good bounce. You could also look at MedTech and Thermo-Fisher.

TOP PICK

World's leader in med tech. He's doubling down on US healthcare. Leader in cardio surgical technology. Healthcare, neglected through Covid, will be a very high growth area for the next couple of years. No dividend. (Analysts’ price target is $49.96)

PARTIAL SELL

Can be a safe haven stock. Health care offers defence. But BSX has had a big run and he expects this market to roll over a bit. Take some profits and wait for opportunities, which could mean buying this back in 2-3 months. Has fantastic fundamentals, but valuation is rich.

BUY

Likes it very much. Higher growth. Under pressure post-earnings. Predominantly everything cardiovascular. Covid put off elective surgeries, and these are starting to return. For the rest of 2022, increased volume might offset inflationary pressures.

WAIT

She has owned it for many years and it has not done anything. The COVID scares cast shadows over medical procedure demand. As a medical device provider it has faced head winds. Demand should ramp back up, but it will take confidence by patients to return for procedures.

PAST TOP PICK

(A Top Pick Dec 01/20, Up 22%) Covid delayed surgeries. Labour shortages. Both are holding the stock back, but will improve. Solid, long-term core investment.

HOLD

Holds other healthcare plays. There is a good place for these names in portfolios. The organic growth from resuming treatment and surgeries will be interesting to follow. Wouldn't worry about the pullback.

WAIT

BSX vs. MDT Two great companies. In the implantable medical device business. Loves the area. Too expensive, as investors have flocked to them and the multiple has increased. Would love to own both if prices came down substantially.

BUY

Medical device maker. It has been a bit of a laggard. It was the market darling until 2019 and then they started to have a couple of misses and issues with products. He thinks these are all transient issues. He thinks in 2022 they will grow revenue in high single digits. He is going to stick with it and would buy it here.

PAST TOP PICK

(A Top Pick Dec 01/20, Up 33%) He would buy it again. They had a decade of no-growth. In the last 3-5 years they introduced successful products that got their revenue going again. A lot of their procedures are not necessary today but will be over the next few months. The volumes are coming back. It is at the cheaper end of a lot of healthcare stocks.

BUY ON WEAKNESS

It's one of Abbott's biggest competitors. It's in an attractive industry, medical equipment, where companies earn good returns. But BSX's valuation is high, gotten ahead of itself (like the whole sector), so wait for a pullback. BSX had a strong quarter as non-elective surgeries have bounced back, but its PE is rich.

Showing 16 to 30 of 72 entries

Most Recent Experts

John Stephenson

Stephenson & Company Capital Management

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Julien Nono-Womdim

Goodreid Investment Council

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Boston Scientific Corp (BSX)